Literature DB >> 8575487

Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.

S Dadparvar1, A Chevres, M Tulchinsky, L Krishna-Badrinath, A S Khan, W J Slizofski.   

Abstract

Recently, technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) has been used to image thyroid carcinoma. A prospective study was performed to compare the efficacy of 99mTc-MIBI to thallium-201 (201Tl) scintigraphy in patients with differentiated thyroid carcinoma. The clinical utility of all radionuclide imaging modalities, i.e., 99mTc-MIBI, 201Tl, and iodine-131 Na (131I-Na), as well as serum thyroglobulin estimation, was evaluated. Thirty-four post-thyroidectomy patients (age range: 26-76 years) underwent 45 studies. Histopathologies studied included fourteen papillary, eight papillary-follicular, ten follicular, one Hürthle cell, and one medullary carcinoma of the thyroid. Following optimal stimulation of endogenous thyroid stimulating hormone (i.e, TSH 50 mU/ml), the patients underwent 201Tl and 99mTc-MIBI scintigraphy. Concomitant 131I-Na scintigraphy was performed and serum thyroglobulin levels were measured. Sixteen scan sets were performed prior to 131I-Na ablation therapy. Twenty-nine scan sets were performed following 131I-Na ablation therapy. The presence or absence of thyroid cancer was established by clinical, biochemical, radiologic, and/or biopsy findings. There was no significant difference in sensitivity and specificity of 201Tl scintigraphy versus 99mTc-MIBI scintigraphy in pre- and postablation studies. 131I-Na scintigraphy with determination of thyroglobulin level was sufficient in preablation studies. Among postablation patients, the addition of 99mTc-MIBI or 201Tl offered a higher diagnostic yield. Between the 201Tl and 99mTc-MIBI studies, there was a concordance of 69% in preablation and 97% among postablation patients (P=0.027). It is concluded that 99mTc-MIBI is a suitable alternative to 201Tl scintigraphy in thyroid carcinoma, especially following thyroidectomy and 131I-Na therapy. 131I-Na scintigraphy with serum thyroglobulin is adequate in both pre- and postablation patients. Among the post-131I-Na ablation patients, 99mTc-MIBI or 201Tl is extremely valuable for tumor localization, especially when the 131I-Na whole-body scan is negative. The combination of 99mTc-MIBI or 201Tl scintigraphy with 131I-Na and serum thyroglobulin offers the highest diagnostic yield.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575487     DOI: 10.1007/bf00801623

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  22 in total

1.  The current and future use of tumor-localizing agents.

Authors:  M Davis
Journal:  J Nucl Med       Date:  1990-10       Impact factor: 10.057

2.  Diffuse uptake of technetium-99m pertechnetate in a patient with metastases from thyroid carcinoma.

Authors:  J F Bouvier; E You; J Y Peau; J L Chassard; B E Lahneche
Journal:  Clin Nucl Med       Date:  1986-10       Impact factor: 7.794

3.  Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes.

Authors:  D Piwnica-Worms; B L Holman
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

4.  Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.

Authors:  L I Delmon-Moingeon; D Piwnica-Worms; A D Van den Abbeele; B L Holman; A Davison; A G Jones
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

5.  The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma.

Authors:  S Dadparvar; L Krishna; L W Brady; W J Slizofski; S J Brown; A Chevres; B Micaily
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

6.  Visualization of suppressed thyroid tissue by Tc-99m MIBI.

Authors:  C H Kao; W Y Lin; S J Wang; S H Yeh
Journal:  Clin Nucl Med       Date:  1991-11       Impact factor: 7.794

7.  Role of technetium-99m sestamibi in localisation of thyroid cancer metastases.

Authors:  F X Sundram; A S Goh; E S Ang
Journal:  Ann Acad Med Singapore       Date:  1993-07       Impact factor: 2.473

8.  Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile.

Authors:  I Földes; A Lévay; G Stotz
Journal:  Eur J Nucl Med       Date:  1993-04

9.  Accumulation of iodine-131 and technetium-99m pertechnetate in thyroid carcinoma.

Authors:  M Katagiri; S Suzuki; S Sadahiro; K Kubouchi; T Ohmura; O Tsumura; S Akatsuka
Journal:  Clin Nucl Med       Date:  1988-04       Impact factor: 7.794

10.  Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging.

Authors:  F J Wackers; D S Berman; J Maddahi; D D Watson; G A Beller; H W Strauss; C A Boucher; M Picard; B L Holman; R Fridrich
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

View more
  5 in total

1.  99mTc-MIBI imaging in thyroid nodules: is it useful?

Authors:  Raffaele Giubbini; Francesco Bertagna
Journal:  Endocrine       Date:  2014-02-28       Impact factor: 3.633

2.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

3.  Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Authors:  Michael E Spieth; Steven B Standiford; Marjorie E Starkman; John Gough
Journal:  Clin Med Res       Date:  2003-01

4.  Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.

Authors:  Masahiro Iwata; Kanji Kasagi; Takashi Misaki; Keiichi Matsumoto; Yasuhiro Iida; Takayoshi Ishimori; Yuji Nakamoto; Tatsuya Higashi; Tsuneo Saga; Junji Konishi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

Review 5.  Parathyroid Imaging: Past, Present, and Future.

Authors:  Michael A Morris; Babak Saboury; Mark Ahlman; Ashkan A Malayeri; Elizabeth C Jones; Clara C Chen; Corina Millo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-25       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.